Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) Cost of Revenue (2016 - 2025)

Rockwell Medical (RMTI) has disclosed Cost of Revenue for 16 consecutive years, with $531000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cost of Revenue fell 97.59% year-over-year to $531000.0, compared with a TTM value of $22.8 million through Sep 2025, down 80.18%, and an annual FY2024 reading of $84.0 million, up 12.14% over the prior year.
  • Cost of Revenue was $531000.0 for Q3 2025 at Rockwell Medical, up from -$14.6 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $52.3 million in Q4 2023 and bottomed at -$49.7 million in Q4 2022.
  • Average Cost of Revenue over 5 years is $9.7 million, with a median of $16.9 million recorded in 2022.
  • The sharpest move saw Cost of Revenue surged 2504.49% in 2021, then plummeted 3149.62% in 2023.
  • Year by year, Cost of Revenue stood at -$41.1 million in 2021, then fell by 20.97% to -$49.7 million in 2022, then skyrocketed by 205.33% to $52.3 million in 2023, then plummeted by 59.79% to $21.0 million in 2024, then crashed by 97.48% to $531000.0 in 2025.
  • Business Quant data shows Cost of Revenue for RMTI at $531000.0 in Q3 2025, -$14.6 million in Q2 2025, and $15.9 million in Q1 2025.